# Isobavachalcone **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/isobavachalcone **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-04-05 **Evidence Score:** 2 / 10 **Category:** Compound **Also Known As:** 4'-O-methylbavachalcone, Prenylated chalcone from Psoralea, Bu Gu Zhi chalcone, Corylifolia chalcone, Isobavachalcone compound, Psoralea seed chalcone, Cullen corylifolium chalcone ## Overview Isobavachalcone is a naturally occurring chalcone flavonoid isolated primarily from Psoralea corylifolia seeds, characterized by a prenylated hydroxyl structure that drives its bioactivity. It exerts [anti-inflammatory](/ingredients/condition/inflammation) effects chiefly by modulating TLR4 signaling to suppress ICAM-1 expression, alongside demonstrated antiplatelet, antioxidative, and [antimicrobial](/ingredients/condition/immune-support) actions in preclinical models. ## Health Benefits • [Anti-inflammatory](/ingredients/condition/inflammation): Demonstrated in vitro by inhibiting LPS-induced ICAM-1 expression and leukocyte adhesion via TLR4 modulation. • Antiplatelet: Shown to inhibit platelet aggregation in preclinical studies. • Antioxidative: Exhibits antioxidative properties in laboratory settings. • [Antimicrobial](/ingredients/condition/immune-support): Displays antimicrobial effects in preclinical research. • Neuroprotection: Inhibits Aβ42 oligomerization/fibrillization, suggesting potential [neuroprotective](/ingredients/condition/cognitive) benefits. ## Mechanism of Action Isobavachalcone suppresses [inflammation](/ingredients/condition/inflammation) by inhibiting Toll-like receptor 4 (TLR4)-mediated NF-κB activation, thereby reducing transcription of adhesion molecule ICAM-1 and blocking leukocyte-endothelial adhesion. Its antiplatelet activity is linked to inhibition of arachidonic acid-induced thromboxane A2 synthesis and suppression of ADP- and collagen-triggered platelet aggregation pathways. Antioxidative effects arise from direct [free radical scaveng](/ingredients/condition/antioxidant)ing via its phenolic hydroxyl groups and potential upregulation of Nrf2-dependent antioxidant enzymes. ## Clinical Summary Available evidence for isobavachalcone is confined almost entirely to in vitro cell-culture studies and rodent preclinical models, with no published randomized controlled trials in humans as of 2024. In vitro studies using LPS-stimulated human umbilical vein endothelial cells (HUVECs) demonstrated statistically significant reductions in ICAM-1 expression and leukocyte adhesion at micromolar concentrations (1–20 µM). Animal platelet aggregation studies reported inhibition rates ranging from 40–70% at tested doses, depending on the aggregation inducer used. The overall evidence base is early-stage, and extrapolation to human therapeutic dosing remains speculative without pharmacokinetic and clinical trial data. ## Nutritional Profile Isobavachalcone (IBC) is a prenylated chalcone (C₂₀H₂₀O₄, MW 324.37 g/mol) primarily isolated from Psoralea corylifolia (Babchi) seeds and Angelica keiskei (Ashitaba) leaves. It is not a macronutrient or micronutrient source but rather a specialized bioactive polyphenol. Typical concentration in Psoralea corylifolia seed extracts ranges from approximately 0.05–0.3% w/w depending on extraction method. In Ashitaba leaf/stem exudate, IBC co-occurs at roughly 0.1–0.5 mg/g dry weight alongside 4-hydroxyderricin. As a prenylated flavonoid, it exhibits enhanced membrane permeability compared to non-prenylated chalcones, with estimated oral bioavailability in the low-to-moderate range (~10–25% in rodent models), improved by co-administration with lipids or phospholipid complexes. It is lipophilic (LogP ~4.0), suggesting good passive absorption but susceptibility to first-pass hepatic [metabolism](/ingredients/condition/weight-management) via glucuronidation and CYP450 oxidation. No significant vitamin or mineral content; its value lies entirely in its pharmacological bioactive profile. ## Dosage & Preparation No clinically studied dosage ranges are available due to the absence of human trials. Commercial products are sold as ≥98% pure powder for research purposes, without specific dosing guidance. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions No human clinical safety data or established safe dosage ranges currently exist for isolated isobavachalcone supplementation. Because it inhibits platelet aggregation and thromboxane A2 synthesis, concurrent use with anticoagulants (e.g., warfarin, heparin) or antiplatelet drugs (e.g., clopidogrel, aspirin) may theoretically increase bleeding risk. Its parent plant Psoralea corylifolia contains furanocoumarins with documented hepatotoxicity and photosensitizing potential, though isobavachalcone itself has not been independently confirmed as the causative agent. Use during pregnancy or lactation is not recommended due to the complete absence of safety data in these populations. ## Scientific Research No human clinical trials or meta-analyses have been conducted on isobavachalcone. The existing evidence is based exclusively on in vitro and preclinical studies without any PubMed PMIDs for human studies. ## Historical & Cultural Context Psoralea corylifolia, from which isobavachalcone is derived, has been used in Chinese herbal medicine. It is traditionally used for its [anti-inflammatory](/ingredients/condition/inflammation), [antiviral](/ingredients/condition/immune-support), and anti-cancer properties, although specific historical uses of isobavachalcone are not detailed. ## Synergistic Combinations IBC pairs synergistically with curcumin (200–500 mg), as both modulate NF-κB signaling through complementary upstream targets—IBC via TLR4 suppression and curcumin via IKKβ inhibition—yielding enhanced [anti-inflammatory](/ingredients/condition/inflammation) output. Piperine (5–10 mg from black pepper) should be included as it inhibits UDP-glucuronosyltransferase and CYP3A4, significantly boosting oral bioavailability of both IBC and curcumin by 1.5–2×. Epigallocatechin gallate (EGCG, 200–300 mg from green tea) complements IBC's antioxidative capacity through Nrf2 pathway co-activation and provides additional anti-amyloid aggregation effects that synergize with IBC's Aβ42 oligomerization inhibition. Finally, omega-3 fatty acids (EPA/DHA, 1–2 g) serve as both a lipid carrier to enhance IBC's intestinal absorption and as a convergent anti-inflammatory agent via resolvins and protectins, amplifying the overall resolution of inflammation. ## Frequently Asked Questions ### What plant does isobavachalcone come from? Isobavachalcone is found primarily in the seeds of Psoralea corylifolia (also called Bakuchi or補骨脂), a plant used in traditional Ayurvedic and Chinese medicine. It has also been identified in smaller quantities in other Leguminosae family plants such as Erythrina variegata. The compound belongs to the prenylated chalcone subclass, distinguished by an isopentenyl group on its aromatic ring. ### Does isobavachalcone have antimicrobial properties? Yes, isobavachalcone has demonstrated antimicrobial activity in laboratory studies against several bacterial and fungal strains, with minimum inhibitory concentrations (MICs) reported in the range of 8–64 µg/mL against organisms including Staphylococcus aureus and Candida albicans. Its prenylated chalcone structure is believed to disrupt microbial membrane integrity. However, these findings are in vitro only, and no human or animal infection trials have been conducted. ### Can isobavachalcone help with inflammation? Preclinical data shows isobavachalcone inhibits LPS-induced inflammatory signaling by targeting TLR4, leading to suppressed NF-κB activation and reduced ICAM-1 expression on endothelial cells at concentrations of 1–20 µM in cell studies. This prevents leukocyte adhesion, an early step in inflammatory cascades. No human clinical trials have confirmed these effects, so calling it a proven anti-inflammatory supplement for humans is premature. ### Is isobavachalcone safe to take with blood thinners? Isobavachalcone should be used with caution alongside anticoagulant or antiplatelet medications such as warfarin, aspirin, or clopidogrel, because preclinical studies indicate it inhibits platelet aggregation through thromboxane A2 suppression, potentially compounding bleeding risk. No formal drug-interaction studies in humans have been performed to quantify this risk. Anyone on blood-thinning therapy should consult a healthcare provider before using products standardized for isobavachalcone. ### What is the difference between isobavachalcone and bavachalcone? Isobavachalcone and bavachalcone are both prenylated chalcones from Psoralea corylifolia but differ in the position of their prenyl and hydroxyl substituents on the aromatic rings, resulting in distinct three-dimensional configurations and slightly different bioactivity profiles. Isobavachalcone carries the prenyl group at the 4'-position of the A-ring, while the positioning differs in bavachalcone, affecting receptor binding affinity and metabolic stability. Both compounds have been studied for anti-inflammatory and antimicrobial properties, but their potency and selectivity toward specific molecular targets are not identical. ### What does research show about isobavachalcone's effectiveness for neuroprotection? Preclinical studies indicate that isobavachalcone may offer neuroprotective benefits by inhibiting the oligomerization of amyloid-beta 42 (Aβ42), a protein implicated in neurodegenerative conditions. However, most evidence comes from laboratory and animal studies, and human clinical trials are limited, making it premature to confirm efficacy in people. More research is needed to establish effective doses and real-world neurological benefits in humans. ### Who should avoid isobavachalcone supplements? People taking antiplatelet or anticoagulant medications should consult a healthcare provider before using isobavachalcone, as preclinical research suggests it may inhibit platelet aggregation. Pregnant and nursing women should avoid supplementation due to insufficient safety data in these populations. Those with bleeding disorders or scheduled for surgery should also seek medical guidance before use. ### How strong is the current evidence for isobavachalcone's antioxidative and anti-inflammatory effects? Evidence for isobavachalcone's antioxidative and anti-inflammatory properties comes primarily from in vitro (test-tube) and preclinical studies, which demonstrate mechanisms such as TLR4 modulation and inhibition of ICAM-1 expression. While these findings are promising, they have not been robustly validated in human clinical trials, limiting conclusions about real-world efficacy and relevance. The translation from laboratory results to therapeutic benefit in humans remains to be established through further research. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*